Vise Technologies Inc. Invests $1.80 Million in Zoetis Inc. $ZTS

Vise Technologies Inc. bought a new stake in shares of Zoetis Inc. (NYSE:ZTSFree Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,555 shares of the company’s stock, valued at approximately $1,802,000.

A number of other institutional investors also recently bought and sold shares of the stock. Nova Wealth Management Inc. purchased a new position in shares of Zoetis in the 1st quarter valued at approximately $25,000. 1248 Management LLC purchased a new position in Zoetis in the first quarter worth about $27,000. Saudi Central Bank purchased a new stake in Zoetis during the 1st quarter valued at $29,000. REAP Financial Group LLC boosted its position in shares of Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares during the last quarter. Finally, NewSquare Capital LLC grew its stake in shares of Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares during the period. 92.80% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ZTS. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Stifel Nicolaus set a $140.00 target price on shares of Zoetis in a research report on Tuesday, November 4th. Argus restated a “buy” rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Finally, BTIG Research reduced their target price on shares of Zoetis from $200.00 to $160.00 and set a “buy” rating on the stock in a report on Wednesday. Six analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $180.00.

Check Out Our Latest Stock Report on ZTS

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $120.09 on Wednesday. Zoetis Inc. has a one year low of $117.26 and a one year high of $181.85. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The firm’s 50 day simple moving average is $142.82 and its 200-day simple moving average is $152.16. The firm has a market cap of $52.92 billion, a PE ratio of 20.67, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTSGet Free Report) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is presently 33.67%.

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Further Reading

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.